NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 75.9% in February

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 926,133 shares, a decrease of 75.9% from the February 12th total of 3,839,273 shares. Based on an average daily trading volume, of 665,099 shares, the days-to-cover ratio is currently 1.4 days. Approximately 6.4% of the shares of the company are short sold. Approximately 6.4% of the shares of the company are short sold. Based on an average daily trading volume, of 665,099 shares, the days-to-cover ratio is currently 1.4 days.

NovaBay Pharmaceuticals Trading Up 1.6%

NYSEAMERICAN NBY traded up $0.02 on Tuesday, hitting $1.26. 320,912 shares of the company’s stock traded hands, compared to its average volume of 477,805. The firm’s 50-day moving average price is $20.65 and its two-hundred day moving average price is $13.35. The firm has a market capitalization of $32.66 million, a PE ratio of -0.13 and a beta of 0.25. NovaBay Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $99.75.

Institutional Trading of NovaBay Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in NovaBay Pharmaceuticals by 2,331.7% during the fourth quarter. Geode Capital Management LLC now owns 1,257,705 shares of the biopharmaceutical company’s stock valued at $7,098,000 after acquiring an additional 1,205,984 shares in the last quarter. State Street Corp lifted its holdings in NovaBay Pharmaceuticals by 970.5% in the fourth quarter. State Street Corp now owns 313,703 shares of the biopharmaceutical company’s stock valued at $1,769,000 after acquiring an additional 284,400 shares during the period. Goldman Sachs Group Inc. purchased a new stake in NovaBay Pharmaceuticals in the 4th quarter worth approximately $588,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of NovaBay Pharmaceuticals during the 4th quarter worth approximately $526,000. Finally, Jane Street Group LLC acquired a new stake in shares of NovaBay Pharmaceuticals during the 4th quarter worth approximately $395,000. Hedge funds and other institutional investors own 23.25% of the company’s stock.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.